 |
|
2006: OGT launches its first microarray product. Appointment of Dr John Anson as Research and Development Director
2005: Appointment of Dr Mike Evans as Chief Executive and Mr James Clough as Commercial Director. Dr David Owen appointed to board as a Non-Executive Director.
2003: Oxford Gene Technology Services Business Unit established to enable access to DNA Microarrays by providing a complete end-to-end service from protocol consultation to
data interpretation.
2003: Oxamer Business Unit established to develop and commercialise fabrication methods based on electrochemical (in-situ) synthesis and real time image processing at the molecular level.
2002: Tridend Technologies Business Unit founded to develop and commercialise new chemistries for protein and genomics technologies.
2002: Licensing and Patents Business Unit established; responsible for protecting OGT's intellectual property and out and in-licensing activities.
1999: OGT establishes Oxford Gene Technology (Operations) Limited.
1997: Microarray patents assigned from Oxford University (Isis) to OGT.
1997: First US patent (US5700637) for DNA microarrays granted.
1995: Oxford Gene Technology Limited founded by Professor Edwin Southern to exploit patented technology developed in his research laboratories at Oxford University.
1994: European Patent Specification (EP0373203) for DNA microarrays granted.
1991: First license of fundamental DNA microarray patents issued.
1988: First Patents applied for DNA Microarrays.
|
|
|
